When technology
meets biology
Translating extraordinary technologies to
life-changing therapies.
AI based
drug-design company
A2i Therapeutics Ltd. aims to develop novel therapeutic modulators of the protein ADAR1, a key element of the innate immune system.
A2i is a joint venture of the FutuRx Incubator and Atomwise, utilizing the AtomNet® AI platform and FutuRx’s drug development capabilities to develop proprietary therapeutic candidates for Immun-oncology and autoimmune indications.
Powered By
Harnessing the power of
artificial intelligence
What is AtomNet® Technology:
A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-based Drug Discovery. This type of network came to prominence only a few years ago and has a unique property: it excels at understanding complex concepts as a combination of smaller and smaller pieces of information. This property is a key reason why convolutional networks have produced the world’s best results for image classification, speech recognition, and other longstanding problems.
Challenge
Adenosine-to-Inosine (A-to-I) RNA editing is catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes that bind and edit double-stranded RNA (dsRNA). It is known that alterations in RNA editing occur in over 35 human pathologies, including several neurological disorders, metabolic diseases, and cancers.
Solution
A2i Therapeutics Ltd. aims to develop small molecules as potential inhibitors for ADAR1 in the context of different pathologies. Our primary focus is resisting the resistance with synergy; Inhibition of ADAR1 as a strategy for rendering tumors sensitive to immunotherapy and to overcome resistance to checkpoint blockade.
News and Press Release
Business Wire 2020
Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority
Atomwise 2020
A2i Therapeutics secures seed funding from FutuRx and its investors - Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority - to develop novel small molecule immuno-oncology agents.
Globes 2020
A2i Therapeutics secures seed funding from FutuRx and its investors - Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority - to develop novel small molecule immuno-oncology agents.
